The
discovery that a fake version of the widely used cancer medicine Avastin is
circulating in the United States is raising new fears that the
multibillion-dollar drug-counterfeiting trade is increasingly making inroads in
the U.S.
The practice has largely been relegated to
poor countries with lax regulations. But with more medicines and drug
ingredients for sale in the U.S. being manufactured overseas, American
authorities are afraid more counterfeits will find their way into this country,
putting patients' lives at risk.
The Avastin discovery follows other recent
instances in the U.S. of counterfeiting, involving such drugs as Viagra, the
cholesterol medicine Lipitor and the weight-loss pill Alli.
"We do know there are counterfeits
continuing to try and make their way onto the U.S. supply chain," said
Connie Jung, an associate director in the Food and Drug Administration's office
of drug security.
The FDA announced Tuesday it is investigating
fake vials of Avastin that were sold to at least 19 doctors or clinics,
including 16 sites in California, two in Texas and one in Chicago. Tests showed
the vials did not contain the active ingredient in Avastin, which is given
intravenously in hospitals, clinics and doctors' offices to treat several types
of cancer.
The contents of the vials are still being
analyzed, and the FDA said it has not received any reports of patients who were
harmed.
FDA officials said the counterfeit Avastin was
imported from Britain and distributed by Volunteer Distribution, a wholesaler
based in Gainesboro, Tenn. British regulators notified the FDA about the
products in December, but the agency didn't confirm they were fake until last
week.
The FDA gave assurances Wednesday that the
U.S. remains one of the most secure pharmaceutical markets in the world. But
the news sent cancer doctors scrambling to check their records.
A vial of Avastin could treat up to four people.
But because the treatments are spaced one to two weeks apart, it is not likely
that someone would get more than one infusion from the same vial. And because
these are people facing a life-threatening disease, it is hard to say whether
missing one treatment with the real drug would compromise their care.
Gauging harm from a counterfeit cancer
treatment is nearly impossible, said Dr. Robert C. Young, former president of
the Fox Chase Cancer Center in Philadelphia and now a consultant to cancer
centers.
A colon cancer patient, for example, might
receive 18 to 20 Avastin infusions over six months. Missing one dose seems
unlikely to have a dramatic effect on survival odds, but it's not provable
either way because cancer's course and a patient's response to treatment are
not predictable, he said.
Counterfeits have traditionally been more of a
concern in developing regions like Asia and Latin America, where as many as 30
percent of drugs sold are fake, according to the World Health Organization. The
group estimates just 1 percent of drugs dispensed in the U.S. and other
developed nations are fake.
But incidents of counterfeiting reported by
drugmakers have increased steadily over the decade to more than 1,700 worldwide
last year, though only 6 percent of those were in the U.S. There are few
reliable estimates on the value of the global counterfeit drug trade, though
most place it in the tens of billions.
Counterfeiting has become more prevalent as
pharmaceutical supply chains increasingly stretch across continents. Over 80
percent of the active ingredients used in U.S. pharmaceuticals are now
manufactured overseas, according to a recent congressional report, and experts
say this has made it easier to move counterfeit products into this country.
"With today's transportation networks,
it's no longer a stretch to move these materials from a source in Pakistan or
India to the U.S." said Tom Kubic, president of Pharmaceutical Security
Institute, a trade association set up by two dozen pharmaceutical companies.
In 2005, federal prosecutors indicted 11
employees of a Missouri business on charges of conspiring to sell $42 million
in counterfeit Lipitor. It was manufactured in Costa Rica and illegally
imported to the U.S., where it was sold to wholesalers.
Industry experts also say a combination of big
profits and low penalties has made drug counterfeiting an increasingly
attractive business for criminals in the U.S. and abroad.
A single vial of Avastin sells for $2,500, and
the drug had nearly $2.7 billion in U.S. sales last year, while the sentence
for drug counterfeiting in the United States is about three years in prison.
That compares with 15 years for counterfeiting money.
John Clark, head of global security for Pfizer
Inc., said counterfeiters can make several million dollars quickly and, if
they're caught, get off with as little as six months in jail. He also said
counterfeiters can set up an operation at a fairly low cost — perhaps $50,000,
including about $20,000 for a pill press.
"It's a no-brainer for criminal
organizations that it's worth a gamble," Clark said.
MATTHEW PERRONE
AP
Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.

No comments:
Post a Comment